Business Wire

Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and its partner Samsung Bioepis announced today an agreement with AbbVie (NYSE: ABBV) for the commercialization of IMRALDI, a biosimilar ...
Business Wire

Samsung Bioepis First to Obtain European Commission Approval for a Third Anti-TNF-α Biosimilar with Imraldi ® (adalimumab)

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Imraldi ®, a biosimilar referencing Humira ® 1 (adalimumab), for the treatment of ...
The American Journal of Managed Care

Patient Satisfaction, Drug Survival of Switches to Adalimumab Biosimilars

Posters presented at the EADV Congress highlighted that despite similar efficacy, patient perception can affect satisfaction with the switch from the reference adalimumab to a biosimilar. While ...
MedPage Today

Adalimumab Versus Biosimilars for Psoriasis

Authors of an article in JAMA Dermatology investigated the differences in effectiveness between adalimumab biosimilars (Amjevita and Imraldi) and the adalimumab originator for psoriasis. The ...
MedPage Today

Humira Copycats for Psoriasis Backed by Real-World Outcomes

Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...